P&G Bets on Brand Spending to Reverse Sales Slowdown, with China Outperforming North America

P&G’s Q4: North America Weakness, China Strength

Procter & Gamble reported a marked slowdown in sales growth in its fiscal fourth quarter, with adjusted operating margins slipping 130 basis points to 19.5% as the consumer goods giant stepped up spending on brand building. The deceleration from the prior quarter’s 3% growth underscores headwinds in mature markets and the company’s willingness to sacrifice near-term profits for long-term competitive strength.

North America, accounting for roughly half of sales, was a drag, with revenue down 1%. In contrast, China posted 4% growth, easily outpacing a market that contracted 2%—a sign that P&G’s heightened focus on brand value is gaining traction there. The company also announced plans to rationalize its product lineup to remove complexity, a move that will trim sales growth by 30 to 50 basis points in the coming fiscal year.

Morningstar analysts, who maintained their $155 fair value estimate for the wide-moat stock, see the brand spending as a wise counter to stagnant category growth. Shares fell about 3% on the news, a pullback that could draw attention to the stock’s valuation.

Why the Brand Spending Bet Could Pay Off

Brand Spending as a Competitive Shield

P&G plans to direct roughly 13% of sales—around $13 billion annually—to research, development, and marketing over the next decade. The logic: infusing product improvements across price tiers can blunt the appeal of lower-priced private-label rivals. Rather than chasing volume through broad price cuts, the company is making surgical discounts to drive trial of new offerings, a tactic that preserves margins while defending market share. Early results in China, where P&G grew 4% against a 2% market decline, suggest this playbook can work in a challenging environment.

North America: The Big Test

The home market remains the critical battleground. Sales slipped 1% despite the spending ramp, indicating that the brand investments have yet to overcome subdued demand or heightened promotional intensity. Management’s emphasis on value over volume is prudent, but the proof will be whether North America returns to growth in subsequent quarters. The region’s performance will largely determine if the elevated spending yields a durable turnaround.

Portfolio Simplification’s Double-Edged Sword

Streamlining the product set to remove complexity should free up resources to fund brand support, but the expected 30-50 basis point headwind to sales in fiscal 2027 shows that the cleanup carries near-term pain. If executed well, the leaner portfolio could lift margins and sharpen strategic focus. Investors will need to weigh the growth sacrifice against the potential efficiency gains—and watch for any signs that pruning goes too far and cedes shelf space to competitors.

Key Signals for P&G Investors

• Watch North America organic sales growth over the next two quarters. A rebound would confirm that brand spending is taking hold; another decline would raise doubts about the strategy’s effectiveness in its most important market.
• Track the product rationalization rollout. The projected 30-50 basis point drag on fiscal 2027 revenue is a concrete headwind that management has flagged. Monitor whether the impact matches guidance and whether margins improve as complexity falls.
• Use the $155 fair value estimate as a benchmark. Morningstar’s valuation, backed by a wide-moat rating, implies the stock may be undervalued after the 3% pullback. Investors can compare this to their own assumptions about P&G’s long-term brand power.
• Assess competitive dynamics in key categories. With private-label pressure elevated, watch for any commentary on market share in North America, the pace of innovation launches, and whether surgical discounting drives repeat purchases or merely one-off trial.